We are the region’s only cancer center dedicated solely to the treatment and research of prostate, kidney, bladder and testicular cancers. Our team of over 30 dedicated professionals have one mission: to provide each patient unsurpassed personalized cancer care accomplished through deep heartfelt compassion, extensive and comprehensible education, the most proficient cancer management, and an unparalleled focus on improving survival and quality of life.
We utilize a unique team approach: Dr. Luke and his Clinical Team, Research Coordinators, Treatment Nurses, Pharmacy, Scheduling and Financial staff work simultaneously during a patient’s visit to ensure delivery of the most accurate, personalized, efficient and expert care.
Learn MoreDr. Luke's research team has access to potentially life-prolonging treatments years before they are available to the public. With our access to a growing pipeline of new drugs on clinical trials, UCC has the most available treatment options for urologic cancers compared to all other major centers.
Learn MoreWe understand the financial burdens cancer may cause a patient and their family. We have highly trained and compassionate staff when it comes helping you choose the most appropriate insurance plans and obtaining assistance to minimize your out- of-pocket costs.
Learn MoreDr. Luke takes the time to thoughtfully and thoroughly explain your diagnosis and treatment options. He will not pressure you into any one treatment option; rather, he allows you to make the choice that is best for you. His staff is friendly and professional; they understand that your time is valuable. Dr. Luke and staff helped make an unpleasant situation seem much less scary.
Experts working together for your best outcome.
Cancer research is the only process available to discover and utilize new treatments for cancer patients. The Urology Center & GU Research Network is recognized by thought leaders, patients and pharmaceutical companies as a global leader in research.
Learn MoreWHEN YOU’RE EXHAUSTED FROM CHEMOTHERAPY, the daily task of preparing three square meals or even just dinner may seem like an insurmountable hurdle. But maintaining a good diet is essential during treatment.
On January 8, 2020, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
